ROIV
Roivant Sciences Ltd. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth -15.4% ·
share flow -8.8% ·
net new positions -18.2%
— formula
Broad distribution — falling shares and fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q4 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 131 | +11 | 408.23M | $14.45B | +15 | −3 |
| Q1 2026 | 122 | +5 | 384.63M | $10.65B | +13 | −9 |
| Q4 2025 | 117 | +1 | 374.22M | $8.12B | +3 | −1 |
| Q3 2025 | 19 | +1 | 262.46M | $3.97B | +1 | −1 |
| Q2 2025 | 16 | +1 | 211.12M | $2.38B | +1 | — |
| Q1 2025 | 12 | +1 | 89.39M | $901.93M | +2 | −1 |
| Q4 2024 | 11 | -2 | 96.86M | $1.15B | — | −2 |
| Q3 2024 | 12 | -1 | 85.45M | $986.08M | +1 | −2 |
| Q2 2024 | 13 | — | 92.40M | $976.70M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Viking Global Investors ✦ | 47.81M | -11.6% | $565.59M | 1.8% | ▼ Trim | 3 | SEC ↗ |
| 2 | State Street Global Advisors ✦ (passive) | 20.80M | — | $246.08M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | Geode Capital Management ✦ (passive) | 7.77M | +0.3% | $91.97M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 4 | Geode Capital Management ✦ (passive) | 7.77M | +0.3% | $91.97M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 5 | Adage Capital Partners ✦ | 5.72M | -0.6% | $67.67M | 0.1% | ▼ Trim | 3 | SEC ↗ |
| 6 | Greenlight Capital (DME Capital) ✦ | 5.27M | -0.7% | $62.36M | 3.2% | ▼ Trim | 3 | SEC ↗ |
| 7 | Greenlight Capital (DME Capital) ✦ | 5.27M | -0.7% | $62.36M | 3.2% | ▼ Trim | 3 | SEC ↗ |
| 8 | Greenlight Capital (DME Capital) ✦ | 5.27M | -0.7% | $62.36M | 3.2% | ▼ Trim | 3 | SEC ↗ |
| 9 | Norges Bank ✦ (passive) | 4.43M | +1.1% | $52.44M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 10 | Marshall Wace ✦ | 2.95M | +104.4% | $34.86M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 11 | Citadel Advisors ✦ | 1.80M | -69.6% | $21.35M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 12 | Citadel Advisors ✦ | 1.80M | -69.6% | $21.35M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 13 | T. Rowe Price ✦ | 248.26K | -9.3% | $2.94M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 14 | Gotham Asset Management ✦ | 39.03K | 0.0% | $461,689 | 0.0% | Held | 3 | SEC ↗ |
| 15 | Two Sigma Investments ✦ | 12.10K | -0.9% | $143,143 | 0.0% | ▼ Trim | 3 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Renaissance Technologies | $3.78M | was 0.0% |
| AQR Capital Management | $1.51M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 436 holders, 528.48M shares, $14.35B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer, Director · 144.76K sh · $5.28M
Officer, Director · 17.52K sh · $653,459
Officer, Director · 172.90K sh · $6.43M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology